Drugs / IBI310
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT05363722 | May 2022 → Apr 2023 | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT05118334 | Nov 2021 → Jul 2022 | non-small cell lung carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04945421 | Jul 2021 → Apr 2022 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04868760 | May 2021 → May 2022 | — | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03545971 | Sep 2018 → Sep 2021 | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT07714317 | Jul 2026 → Jul 2027 expected | hepatocellular carcinoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05653180 | Mar → Dec 2023 | biliary tract cancer | Innovent Biologics (Suzhou) Co. Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04202601 | Dec 2019 → Sep 2022 | gastroesophageal adenocarcinoma | Peking University | Unknown | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT07410975 | Jan 2026 → Jun 2028 expected | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Recruiting | No outcome recorded |
| Phase 2 | NCT06620822 | Sep 2024 → Sep 2026 expected | non-small cell lung carcinoma | Shanghai Pulmonary Hospital, Shanghai, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06580574 | Sep 2024 → Jun 2029 expected | colon carcinoma, gastric cancer | Peking University | Recruiting | No outcome recorded |
| Phase 2 | NCT05165407 | Jul 2022 → Sep 2025 overdue | neuroendocrine neoplasm | Peking University | Recruiting | No outcome recorded |
| Phase 2 | NCT04590599 | Dec 2020 → Nov 2023 | cervical cancer | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT04258111 | Aug → Oct 2020 | colorectal cancer | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07490262 | Mar 2026 → Dec 2027 expected | hepatocellular carcinoma | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05890742 | May 2023 → Apr 2028 expected | — | Innovent Biologics (Suzhou) Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04720716 | Feb 2021 → Dec 2025 | hepatocellular carcinoma | Innovent Biologics (Suzhou) Co. Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT04277663 | Apr 2020 → Feb 2023 | acral lentiginous melanoma | Innovent Biologics (Suzhou) Co. Ltd. | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IBI310 | “This is a phase 1b/II, open label, multicenter study of IBI310 (Anti-CTLA4 mAb) in combination with Sintilimab in patients with recurrent/metastatic Nasopharyngeal Carcinoma...” NCT04945421 ↗17“Sintilimab 200mg, ivgtt, q21d; IBI310 1mg/kg, ivgtt, q42d; Lenvatinib 8mg (starting from 4mg), po, qd” NCT06580574 ↗ “Drug: IBI310 1 mg/kg Q6W on Day 1 by IV infusion” NCT04202601 ↗ |
| Action | Inhibit | “anti-CTLA-4 antibody” NCT04258111 ↗ |
| Modality | Monoclonal antibody | “IBI310 (Anti-CTLA4 mAb)” NCT04945421 ↗ |
| Route | Intravenous | “IBI310 0.3mg/kg intravenous every 3 weeks” NCT03545971 ↗ |
| Target | CTLA4 | “anti-CTLA-4 antibody” NCT04258111 ↗ |